“…We recognize, however, that D€ ohner's cohort included a mixture of pre-and posttreatment samples, and, therefore, we also compared our prevalence rates with a more recent clinical trial cohort about to start first-line therapy. As seen in our cohort, deletion of 11q (27,28,30) and deletion of 6q (27,28) have been consistently reported at lower frequencies and, conversely, IGH translocations (12,30e32) and trisomy 12 (10,27) have been reported to occur at higher frequencies. These differences likely reflect variations in the populations studied, including whether they were clinical trial or population-based cohorts.…”